At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓CLL/SLL confirmed by flow cytometry positive for CD19, CD23, and CD5 (CD23 may be negative if cyclin D1 negative)
- ✓Failed at least 1 fludarabine-containing regimen OR at least 2 non-fludarabine-containing regimens OR has contraindication to fludarabine
- ✓ECOG performance status 0-2
- ✕Pregnant or breast-feeding women
- ✕Uncontrolled angina within 3 months
- ✕Diagnosed or suspected congenital long QT syndrome
- ✕History of clinically significant ventricular arrhythmias
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating Dasatinib for Chronic Lymphocytic Leukemia. Completed, enrolled 15 participants across 2 sites.
Detailed Summary
The purpose of this research study is to see if Dasatinib is effective and safe to give to people with relapsed chronic lymphocytic leukemia (CLL) and to determine the effects of the drug on LYN kinase activity in blood and bone marrow. Recent research shows that a key enzyme in CLL cells is responsible for cell survival. This enzyme is called LYN kinase. Laboratory studies show that inhibition of LYN kinase in CLL cells results in the death to CLL cells. Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some effect on CLL cells.
Study Details
Timeline
Interventions
Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.